Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12617000261314
Ethics application status
Approved
Date submitted
17/01/2017
Date registered
20/02/2017
Date last updated
19/02/2018
Type of registration
Retrospectively registered
Titles & IDs
Public title
Blood Ropivacaine level after PECS II block in patients undergoing mastectomy.
Query!
Scientific title
A prospective study of analgesic efficacy and plasma Ropivacaine concentration after PECS II block in patients undergoing mastectomy.
Query!
Secondary ID [1]
290935
0
nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
breast cancer
301657
0
Query!
regional block
301658
0
Query!
mastectomy
301659
0
Query!
Condition category
Condition code
Anaesthesiology
301366
301366
0
0
Query!
Anaesthetics
Query!
Cancer
301477
301477
0
0
Query!
Breast
Query!
Surgery
301478
301478
0
0
Query!
Other surgery
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Venous blood will be sampled from the blood taking canulla at 0, 10, 20, 30, 45, 60, 90, and 120 minutes after PECS II block using Ropivacaine.
Query!
Intervention code [1]
296980
0
Not applicable
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
300763
0
To measure the chronological changes in venous concentration of Ropivacaine after PECS II block.
Query!
Assessment method [1]
300763
0
Query!
Timepoint [1]
300763
0
venous concentration of Ropivacaine at 0, 10, 20, 30, 45, 60, 90, 120 minutes after PECS II block.
Query!
Primary outcome [2]
300959
0
Calculation for the time point of maximum concentration of Ropivacaine occurred (Tmax) after injection of PECS II block,
Query!
Assessment method [2]
300959
0
Query!
Timepoint [2]
300959
0
within two hours after injection of PECS II block.
Query!
Primary outcome [3]
300960
0
Calculation of maximum venous plasma concentration (Cmax).
Query!
Assessment method [3]
300960
0
Query!
Timepoint [3]
300960
0
within two hours after injection of PECS II block.
Query!
Secondary outcome [1]
330809
0
hypodermic needle will be used to test the dermatological extent of the block 30 minutes after Ropivacaine injection.
Query!
Assessment method [1]
330809
0
Query!
Timepoint [1]
330809
0
dermatological extent of the block 30 minutes after Ropivacaine injection.
Query!
Secondary outcome [2]
331280
0
to assess the block duration of the analgesic effect post operation.
Query!
Assessment method [2]
331280
0
Query!
Timepoint [2]
331280
0
The duration of the block will be evaluated by measuring the amount of time that elapsed between completion of the block and the first administration of postoperative rescue analgesia (subcutaneous Morphine 0.1mg/kg).
Query!
Eligibility
Key inclusion criteria
adult female patients undergoing unilateral mastectomy with axillary clearance will be prospectively enrolled.
Inclusion criteria:
- ASA 1, 2 and 3 (without significant liver or renal impairment)
- Age above 18 years old
- Able to give consent
- Body weight > 50kg
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patient’s refusal and inability to give consent or cooperation during procedure
- Allergy or sensitivity to local anaesthetics
- BMI>35
Query!
Study design
Purpose
Natural history
Query!
Duration
Cross-sectional
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
patient undergoing unilateral mastectomy and agreeable for PECS II block will be offered to participate in the study.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2017
Query!
Date of last participant enrolment
Anticipated
30/06/2017
Query!
Actual
8/06/2017
Query!
Date of last data collection
Anticipated
30/06/2017
Query!
Actual
8/06/2017
Query!
Sample size
Target
28
Query!
Accrual to date
Query!
Final
13
Query!
Recruitment outside Australia
Country [1]
8581
0
Malaysia
Query!
State/province [1]
8581
0
Kuala Lumpur
Query!
Funding & Sponsors
Funding source category [1]
295353
0
University
Query!
Name [1]
295353
0
University Malaya Medical Center
Query!
Address [1]
295353
0
Anaesthesiology Department,
University Malaya Medical Center,
Lembah Pantai,
59100
Kuala Lumpur,
Malaysia
Query!
Country [1]
295353
0
Malaysia
Query!
Primary sponsor type
University
Query!
Name
University Malaya
Query!
Address
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia
Query!
Country
Malaysia
Query!
Secondary sponsor category [1]
294177
0
None
Query!
Name [1]
294177
0
Query!
Address [1]
294177
0
Query!
Country [1]
294177
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
296685
0
UMMC Medical Research Ethics Committee (MREC)
Query!
Ethics committee address [1]
296685
0
University Malaya Medical Centre Lembah Pantai,59100 Kuala Lumpur, Malaysia.
Query!
Ethics committee country [1]
296685
0
Malaysia
Query!
Date submitted for ethics approval [1]
296685
0
06/05/2016
Query!
Approval date [1]
296685
0
03/06/2016
Query!
Ethics approval number [1]
296685
0
20165-2443
Query!
Summary
Brief summary
To measure the chronological changes in venous concentration of Ropivacaine after PECS II block, in which the calculation for the time point of maximum concentration of Ropivacaine occurred (Tmax) and maximum venous plama concentration (Cmax) are mandatory. This would determine whether the peak plasma Ropivacaine concentration level is within the safety level allowed. The venous threshold value of systemic toxicity is 2.2 microgram/ml. The result of this study might change future recommended dosing regimen for PECS II block practice using Ropivacaine.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
71774
0
A/Prof Mohd Shahnaz Bin Hasan
Query!
Address
71774
0
Department of Anaethesiology
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia
Query!
Country
71774
0
Malaysia
Query!
Phone
71774
0
+6079492052
Query!
Fax
71774
0
Query!
Email
71774
0
[email protected]
Query!
Contact person for public queries
Name
71775
0
Mohd Shahnaz Bin Hasan
Query!
Address
71775
0
Department of Anaethesiology
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia
Query!
Country
71775
0
Malaysia
Query!
Phone
71775
0
+6079492052
Query!
Fax
71775
0
Query!
Email
71775
0
[email protected]
Query!
Contact person for scientific queries
Name
71776
0
Mohd Shahnaz Bin Hasan
Query!
Address
71776
0
Department of Anaethesiology
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia
Query!
Country
71776
0
Malaysia
Query!
Phone
71776
0
+6079492052
Query!
Fax
71776
0
Query!
Email
71776
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF